Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates

This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.

Study Overview

• Status: Recruiting
• Conditions: Breast Carcinoma; Lung Carcinoma
• Intervention / Treatment: Other: Survey Administration; Behavioral: Health Education; Other: Health Promotion and Education; Behavioral: Patient Navigation

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the number of patients undergoing breast screening who are eligible to participate in lung screening.

II. Determine whether patients currently participating in cancer screening (breast OR lung) are successful as "cancer screening advocates." III. Determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." IV. Identify knowledge base and psychological barriers to screening through surveys of potential screening participants.

OUTLINE:

Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.

After completion of study intervention, participants are followed up yearly for up to 3 years.

• Study Type: Interventional
• Enrollment (Estimated): 800
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • UCLA / Jonsson Comprehensive Cancer Center
      • Contact: Ashley E. Prosper; Phone Number: 310-825-0958; Email: APROSPER@MEDNET.UCLA.EDU
      • Principal Investigator: Ashley E. Prosper

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age:

  • Breast screening > 40
  • Lung screening 50-80
• Male (M) or Female (F)
• Current, former, or never smokers
• Close family or friend with smoking history (in or out of state)

Exclusion Criteria:

• Age:

  • Breast screening < 40
  • Lung screening < 50 or > 80
• Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded
• Persons with an active cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Screening (electronic patient portal, patient navigation); Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.	Other: Survey Administration; Ancillary studies; Behavioral: Health Education; Access electronic patient portal with educational material; Other: Health Promotion and Education; Receive materials on breast/lung cancer screening; Behavioral: Patient Navigation; Interact with a patient navigator; Other Names: Patient Navigator Program

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Increased rates of lung and breast cancer screening adherence	By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.	Up to 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success of "sphere of influence" model	Considered successful if increased lung cancer screening referrals are a direct result of women receiving screening mammograms inviting and educating friends and family about lung cancer screening.	Up to 3 years

Collaborators and Investigators

• Sponsor: Jonsson Comprehensive Cancer Center
• Investigators: Principal Investigator: Ashley E Prosper, UCLA / Jonsson Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2023
• Primary Completion (Estimated): September 30, 2028
• Study Completion (Estimated): September 30, 2029

Study Registration Dates

• First Submitted: July 28, 2023
• First Submitted That Met QC Criteria: July 28, 2023
• First Posted (Actual): August 7, 2023

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Breast Diseases; Breast Neoplasms; Carcinoma
• Other Study ID Numbers: 22-000947; NCI-2023-04133 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No